Immune-checkpoint inhibitors (ICIs) as second-line therapy showed an overall survival (OS) benefit, but only 18-20% of aNSCLC patients respond with a medianprogression-free survival (mPFS) of 2-4 months. The identification of biomarkers to select patients most likely to benefit from ICIs is still an unmet need in clinical practice.
87PTime-series of peripheral blood biomarkers as biomarkers for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients
Bilancia, M;Montrone, M;Pesola, F;Varesano, N;Ricci, D;
2019-01-01
Abstract
Immune-checkpoint inhibitors (ICIs) as second-line therapy showed an overall survival (OS) benefit, but only 18-20% of aNSCLC patients respond with a medianprogression-free survival (mPFS) of 2-4 months. The identification of biomarkers to select patients most likely to benefit from ICIs is still an unmet need in clinical practice.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
mdz067.004.pdf
accesso aperto
Descrizione: articolo principale
Tipologia:
Documento in Versione Editoriale
Licenza:
Creative commons
Dimensione
78.11 kB
Formato
Adobe PDF
|
78.11 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
